# Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients

> **NCT02990312** · PHASE4 · WITHDRAWN · sponsor: **University of Maryland, Baltimore**

## Conditions studied

- Hiv
- Kidney Transplant
- HIV Reservoir
- CCR5

## Interventions

- **DRUG:** Sirolimus + Maraviroc

## Key facts

- **NCT ID:** NCT02990312
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-05-01
- **Primary completion:** 2019-07-17
- **Final completion:** 2019-07-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2019-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02990312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02990312, "Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02990312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*